Description
Bohemine is a purine derivative that inhibits cyclin-dependent kinases (CDKs) and exhibits anticancer activity. Bohemine suppresses cell growth and induces G1 and G2 phase cell cycle arrest in hybridoma cells.
Product Info
| Cas No. | 189232-42-6 |
|---|---|
| Purity | ≥98% |
| Formula | C18H24N6O |
| Formula Wt. | 340.43 |
| Chemical Name | 3-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)propan-1-ol |
| IUPAC Name | 3-{[6-(Benzylamino)-9-isopropyl-9H-purin-2-yl]amino}-1-propanol |
| Synonym | 3-{[6-(benzylamino)-9-(propan-2-yl)-9h-purin-2-yl]amino}propan-1-ol; CHEMBL83980; CHEBI:86007 |
| Solubility | >17mg/ml in DMSO |
Shipping and Storage
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
Downloads
| MSDS | |
|---|---|
| Info Sheet |
References
Kovarova H, Halada P, Man P, et al. Application of proteomics in the search for novel proteins associated with the anti-cancer effect of the synthetic cyclin-dependent kinases inhibitor, bohemine. Technol Cancer Res Treat. 2002 Aug;1(4):247-56. PMID: 12625783.
Franek F, Strnad M, Havlícek L, et al. Diverse effects of the cyclin-dependent kinase inhibitor bohemine: Concentration- and time-dependent suppression or stimulation of hybridoma culture. Cytotechnology. 2001 Jul;36(1-3):117-23. PMID: 19003322.